Protease,Integrase and Entry inhibitor dose
HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
... To cite this article: Maile Y. Karris, Sonia Jain, Tyler R.C. Day, Josué Pérez-Santiago, Miguel Goicoechea, Michael P. Dubé, Xiaoying Sun, Celsa Spina, Eric S. Daar, Richard H. Haubrich, Sheldon Morris & for the ...
10
HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
... HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability presents a challenge to laboratories performing genotypic resistance ...
13
Cross clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
... to integrase inhibitors in addition to reverse transcription inhibitors and protease inhibitors with a single amplicon, and finally, simultaneous genotyping of all major group M HIV subtypes with a single ...
15
The prototype foamy virus protease is active independently of the integrase domain
... the protease-reverse transcriptase (PR-RT) exhibits protease activity in vitro and in vivo, which is independent of the integrase ...the integrase domain. To further analyse the regulation of ...
8
Foamy Retrovirus Integrase Contains a Pol Dimerization Domain Required for Protease Activation
... National Cancer Research Institute-Frederick, Frederick, Maryland 21702 3 Received 3 September 2009/Accepted 8 November 2010 Unlike orthoretroviruses, foamy retroviruses (FV) synthesize Pol independently of Gag. The FV ...
7
Progress in development of HIV 1 integrase inhibitor
... HIV protease occurs, leading to morphological maturation of ...HIV-1 protease inhibitors [5, 6], respectively, have been developed, and in abundance are available structure- activity relationship (SAR) ...
15
Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patients
... Antiretroviral, Integrase inhibitor, HIV INTRODUCTION With the use of antiretroviral of high potency, tolerability, and resistance profiles, lifespan time has increased for HIV patients but even after so ...
8
Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance
... of integrase inhibitors expands to use within more diverse populations, different antiretro- viral combinations, and to different clinical settings, a more detailed understanding of the overall genetic barrier to ...
12
Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease
... (FIV) protease is structurally very similar to human immunodeficiency virus (HIV) protease but exhibits distinct substrate and inhibitor ...FIV protease in order to define interactions that ...
11
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients
... a dose of 400 mg of lopinavir and 100 mg of RTV twice daily) are ⱖ75-fold above the serum-adjusted IC 50 of lopinavir against wt HIV (18), we required the identification of sets of mutations asso- ciated with ...
8
SOLUBILITY ENHANCEMENT OF POORLY WATER SOLUBLE PROTEASE INHIBITOR
... Higher dose is administered to achieve desired pharmacological effect as undissolved dose is excreted as ...high dose exhibits erratic absorption patterns, non linear pharmacokinetics and are highly ...
7
Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection
... Given these results, we hypothesized that AEBSF needed to be present during the entry phase of RSV. In order to test this, we adapted the previous setup of the time-of-addition experiments to inoculation for 2 h ...
10
Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen
... Reverse transcriptase gene. For the coding region of the re- verse transcriptase gene, the M184V/I mutation was detected by bulk sequencing in all seven patients during first regimen failure. This was expected as all ...
7
Identification of a Broad-Spectrum Arenavirus Entry Inhibitor
... inhibitory concentrations (IC 50 s) were calculated using XLfit (IDBS) for Mi- crosoft Excel with a one-site dose-response curve fit. RESULTS Identification and activity of ST-193. A chemically diverse, random ...
8
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
... Data processing. All cell-free experiments, except when otherwise in- dicated, were the result of at least 3 sets of experiments, performed in triplicate to yield 9 independent values. To determine the kinetic param- ...
10
Protease-Mediated Entry via the Endosome of Human Coronavirus 229E
... of protease inhibitors on infection with ...by protease in- ...of protease inhibitors were infected with pseudotypes bearing 229E S, SARS-CoV S, or VSV G, and their infection levels were estimated ...
10
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
... Different classes of antiretroviral drugs display characteristic dose–response curve slopes in antiviral activity assays, which has important implications for the mechanism of drug action. IN is considered a ...
7
In vitro activity of dolutegravir against wild type and integrase inhibitor resistant HIV 2
... Curve fits were generated as described in Figure 1A. (D) Comparative analysis of equivalent site-directed mutants of HIV-1 and HIV-2 integrase. Each point is the result of a single dose-response assay ...
9
Outcome of protease inhibitor substitution with nevirapine in HIV 1 infected children
... transcriptase inhibitor (NRTI) plus 1 or 2 PIs) for at least 6 consecutive months; they were naive to non nucleoside reverse transcriptase inhibitor ...study entry and a sta- ble clinical and ...
7
Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo
... The profound clinical efficacy of the new class of HIV anti- retrovirals, INIs, and the unexpectedly rapid kinetics of HIV-1 RNA load reduction of raltegravir emphasize the need to in- vestigate basic pharmacovirological ...
12